echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > More than 70 rare disease drugs have been listed in China

    More than 70 rare disease drugs have been listed in China

    • Last Update: 2021-06-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    So far, based on the "First List of Rare Diseases", China has marketed more than 70 rare disease-related drugs, involving more than 60 rare diseases
    .
    Patients with these rare diseases have realized "there are medicines to cure"
    .
    At the same time, high-value drugs for rare diseases ("orphan drugs") have also entered the fast lane to market
    .
    A multidisciplinary expert seminar on the prevention and control of urea cycle disorders, co-sponsored by the National Association of Rare Diseases Academic Association Chairmen Meeting, Shanghai Rare Disease Prevention and Treatment Foundation and Shanghai Medical Association Rare Disease Specialist Branch, was held here on the 19th
    .
    The heads of rare disease academic organizations across China, experts in related fields such as clinical medicine, pharmacy, law, policy research, and health economics, and business people have jointly faced the opportunities and challenges of the rare disease drug protection mechanism and provided suggestions
    .
    It is reported that about 7,000 rare diseases have been discovered in the world, 80% of which are genetic diseases, and about half of rare diseases are children.
    Among the deaths of infants under 1 year old, about 35% are caused by rare diseases
    .
    It is understood that in recent years, China has issued a series of policies to promote the development of rare disease prevention and protection
    .
    At the same time, with the reform and development of the national medical and health system, the drug review and approval process continues to be optimized.
    In 2019 and 2020, a variety of high-value drugs were approved in China, giving rare disease patients and their families hope
    .
      In recent years, the introduction of rare disease drugs into China and their inclusion in the national medical insurance catalogue have been increasing year by year
    .
    During the interview, the reporter learned that with the approval of related treatment drugs in China, long-term treatment of patients with urea cycle disorders and the improvement of their quality of life have new guarantees
    .
    It is reported that urea cycle disorder (UCD) is an autosomal recessive inherited disease
    .
    Early onset of neonates has a high mortality rate; late-onset diseases can lead to mental retardation and death
    .
      At the seminar, the reporter learned that Shanghai, Qingdao, Zhejiang, Foshan and other places have explored mechanisms for guaranteeing drugs for rare diseases
    .
    Localities have brought the gospel to patients by including rare diseases in the medical insurance for major diseases, establishing a special fund system, implementing government-type commercial insurance, encouraging participation in medical assistance, advocating charitable assistance, corporate donations, and a certain proportion of individual self-payment
    .
      During the interview, the reporter learned that there are still many limitations in the exploration of various regions, such as: the personal pay ratio is very different in different places; the number of rare disease patients is small, and the room for drug price negotiation is limited; the product design of policy-based commercial insurance is not mature enough in the rapid development.
    It is difficult to form a long-term mechanism and so on
    .
    Li Dingguo, chairman of the Shanghai Rare Disease Prevention and Control Foundation, told reporters that rare diseases are not only medical issues but also social issues
    .
    Rare diseases have been neglected due to their low incidence, limited treatment methods, and low social awareness of rare diseases
    .
    Difficulty in discovery, treatment, inability to use drugs, and inability to use drugs have always been one of the important reasons that plague patients with rare diseases and their families
    .
    He believes that promoting the prevention and treatment of rare diseases is a symbol of the progress of social civilization
    .
      Professor Yang Yanling, a professor of pediatrics at Peking University First Hospital, said that for rare diseases and genetic diseases, we should be able to prevent and treat all diseases
    .
    The expert said frankly that 80% of rare diseases are inherited metabolic diseases, and most inherited diseases are recessive inheritance.
    From the perspective of prevention and control, it is very difficult, so it must be cured
    .
      Huang Guoying, the dean of the Children's Hospital of Fudan University, said frankly that exploring the drug security mechanism for rare diseases is a gradual process, and it is also a process of continuous enrichment and improvement with the country's economic and social development
    .
    He hopes that industry-university-research-medicine will be combined, and enterprises will actively cooperate with medical institutions to jointly develop drugs and equipment for the diagnosis and treatment of rare diseases
    .
      Wang Lin, secretary-general of the Joint Conference of Chairpersons of National Rare Disease Academic Societies, told reporters that the prevention and treatment of rare diseases is consistent with prenatal and postnatal care and the improvement of the overall quality of the Chinese nation
    .
    Wang Lin believes that rare disease drugs should be included in the medical insurance list as much as possible to share the financial pressure for families with rare diseases.
    This is a problem worthy of discussion
    .
    She believes that it is particularly urgent to establish a government-led multi-party co-payment mechanism for rare disease drugs.
    It is necessary to solve the problem of rare disease legislation and establish a rare disease database in China
    .
      It is understood that in recent years, the development of China's rare disease cause has brought opportunities and challenges for pharmaceutical companies
    .
    The optimization and reform of the drug review and approval process has greatly shortened the window period for rare disease drugs to be marketed
    .
    The efforts of enterprises have improved the medication protection for patients with rare diseases
    .
      During the interview, many experts said that in the process of seeking development, enterprises must adhere to both economic and social benefits
    .
    It is reported that most high-value drugs for rare diseases rely on imports and are expensive
    .
    Companies must reasonably reduce the cost of medication for patients in order to improve the availability of drugs among patients with rare diseases and increase independent research and development of drugs for rare diseases
    .
    (China News Network)
    So far, based on the "First List of Rare Diseases", China has marketed more than 70 rare disease-related drugs, involving more than 60 rare diseases
    .
    Patients with these rare diseases have realized "there are medicines to cure"
    .
    At the same time, high-value drugs for rare diseases ("orphan drugs") have also entered the fast lane to market
    .
      A multidisciplinary expert seminar on the prevention and control of urea cycle disorders, co-sponsored by the National Association of Rare Diseases Academic Association Chairmen Meeting, Shanghai Rare Disease Prevention and Treatment Foundation and Shanghai Medical Association Rare Disease Specialist Branch, was held here on the 19th
    .
    The heads of rare disease academic organizations across China, experts in related fields such as clinical medicine, pharmacy, law, policy research, and health economics, and business people have jointly faced the opportunities and challenges of the rare disease drug protection mechanism and provided suggestions
    .
      It is reported that about 7,000 rare diseases have been discovered in the world, 80% of which are genetic diseases, and about half of rare diseases are children.
    Among the deaths of infants under 1 year old, about 35% are caused by rare diseases
    .
      It is understood that in recent years, China has issued a series of policies to promote the development of rare disease prevention and protection
    .
    At the same time, with the reform and development of the national medical and health system, the drug review and approval process continues to be optimized.
    In 2019 and 2020, a variety of high-value drugs were approved in China, giving rare disease patients and their families hope
    .
      In recent years, the introduction of rare disease drugs into China and their inclusion in the national medical insurance catalogue have been increasing year by year
    .
    During the interview, the reporter learned that with the approval of related treatment drugs in China, long-term treatment of patients with urea cycle disorders and the improvement of their quality of life have new guarantees
    .
    It is reported that urea cycle disorder (UCD) is an autosomal recessive inherited disease
    .
    Early onset of neonates has a high mortality rate; late-onset diseases can lead to mental retardation and death
    .
      At the seminar, the reporter learned that Shanghai, Qingdao, Zhejiang, Foshan and other places have explored mechanisms for guaranteeing drugs for rare diseases
    .
    Localities have brought the gospel to patients by including rare diseases in the medical insurance for major diseases, establishing a special fund system, implementing government-type commercial insurance, encouraging participation in medical assistance, advocating charitable assistance, corporate donations, and a certain proportion of individual self-payment
    .
      During the interview, the reporter learned that there are still many limitations in the exploration of various regions, such as: the personal pay ratio is very different in different places; the number of rare disease patients is small, and the room for drug price negotiation is limited; the product design of policy-based commercial insurance is not mature enough in the rapid development.
    It is difficult to form a long-term mechanism and so on
    .
    Li Dingguo, chairman of the Shanghai Rare Disease Prevention and Control Foundation, told reporters that rare diseases are not only medical issues but also social issues
    .
    Rare diseases have been neglected due to their low incidence, limited treatment methods, and low social awareness of rare diseases
    .
    Difficulty in discovery, treatment, inability to use drugs, and inability to use drugs have always been one of the important reasons that plague patients with rare diseases and their families
    .
    He believes that promoting the prevention and treatment of rare diseases is a symbol of the progress of social civilization
    .
      Professor Yang Yanling, a professor of pediatrics at Peking University First Hospital, said that for rare diseases and genetic diseases, we should be able to prevent and treat all diseases
    .
    The expert said frankly that 80% of rare diseases are inherited metabolic diseases, and most inherited diseases are recessive inheritance.
    From the perspective of prevention and control, it is very difficult, so it must be cured
    .
      Huang Guoying, the dean of the Children's Hospital of Fudan University, said frankly that exploring the drug security mechanism for rare diseases is a gradual process, and it is also a process of continuous enrichment and improvement with the country's economic and social development
    .
    He hopes that industry-university-research-medicine will be combined, and enterprises will actively cooperate with medical institutions to jointly develop drugs and equipment for the diagnosis and treatment of rare diseases
    .
      Wang Lin, secretary-general of the Joint Conference of Chairpersons of National Rare Disease Academic Societies, told reporters that the prevention and treatment of rare diseases is consistent with prenatal and postnatal care and the improvement of the overall quality of the Chinese nation
    .
    Wang Lin believes that rare disease drugs should be included in the medical insurance list as much as possible to share the financial pressure for families with rare diseases.
    This is a problem worthy of discussion
    .
    She believes that it is particularly urgent to establish a government-led multi-party co-payment mechanism for rare disease drugs.
    It is necessary to solve the problem of rare disease legislation and establish a rare disease database in China
    .
      It is understood that in recent years, the development of China's rare disease cause has brought opportunities and challenges for pharmaceutical companies
    .
    The optimization and reform of the drug review and approval process has greatly shortened the window period for rare disease drugs to be marketed
    .
    The efforts of enterprises have improved the medication protection for patients with rare diseases
    .
      During the interview, many experts said that in the process of seeking development, enterprises must adhere to both economic and social benefits
    .
    It is reported that most high-value drugs for rare diseases rely on imports and are expensive
    .
    Companies must reasonably reduce the cost of medication for patients in order to improve the availability of drugs among patients with rare diseases and increase independent research and development of drugs for rare diseases
    .
    (China News Network)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.